Get the Stockscreener App
71.23
1.06%
-0.76
After Hours:
71.23
Ani Pharmaceuticals Inc stock is traded at $71.23, with a volume of 219.22K.
It is down -1.06% in the last 24 hours and down -10.06% over the past month.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
See More
Previous Close:
$71.99
Open:
$71.35
24h Volume:
219.22K
Relative Volume:
0.64
Market Cap:
$1.64B
Revenue:
$923.71M
Net Income/Loss:
$84.68M
P/E Ratio:
18.07
EPS:
3.9419
Net Cash Flow:
$182.81M
1W Performance:
-2.20%
1M Performance:
-10.06%
6M Performance:
-6.93%
1Y Performance:
-25.80%
1-Day Range:
$71.11
$72.06
1-Week Range:
$71.11
$74.99
52-Week Range:
$70.15
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(609) 759-1810
Address
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
71.23 | 1.78B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board - Yahoo Finance
ANI Pharmaceuticals to Present at September Investor Conferences - globenewswire.com
Corient Private Wealth LP Invests $2.01 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) SVP & CFO Stephen Carey Sells 2,850 S - GuruFocus
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $207,480 in stock - Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares - MarketBeat
79,683 Shares in ANI Pharmaceuticals, Inc. $ANIP Purchased by Jupiter Topco LLC - MarketBeat
ANI Pharmaceuticals (ANIP) CFO sells 2,850 shares in preset trading plan - Stock Titan
Penn Capital Management Company LLC Boosts Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Man Group plc Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Precision Trading with Ani Pharmaceuticals Inc. (ANIP) Risk Zones - news.stocktradersdaily.com
Freestone Grove Partners LP Takes $8.39 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Sanctuary Advisors LLC Makes New $1.14 Million Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
ANI Pharmaceuticals (ANIP) director reports holding zero shares - Stock Titan
PDT Partners LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
How Investors Are Reacting To ANI Pharmaceuticals (ANIP) Board Shake-Up And Strategic Expertise Addition - simplywall.st
ANI Pharmaceuticals (ANIP) President & CEO Nikhil Lalwani Sells 5,400 Shares - GuruFocus
Ani Pharmaceuticals CEO sells $401,220 in company stock By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $401,220.00 in Stock - MarketBeat
ANI Pharmaceuticals (ANIP) CEO sells 5,400 shares under trading plan - Stock Titan
Nikhil Lalwani plans ANI (NASDAQ: ANIP) stock sale topping $400K - Stock Titan
Is ANI Pharmaceuticals (ANIP) Fairly Priced After Its Board Change? - Sahm
ANI Pharmaceuticals adds Henry Gosebruch to board of directors - Investing.com
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors - The Manila Times
ANI Pharmaceuticals adds Henry Gosebruch to board of directors By Investing.com - Investing.com South Africa
William Blair Investment Management LLC Takes $21.37 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (ANIP) Faces A Fresh Valuation Test Following Strong 2026 Results - Sahm
NFJ Investment Group LLC Takes $2.77 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Virtus Advisers LLC Makes New Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI (ANIP): Rises 1.37% to $77.92 for the Current Session; Boundary Watch: $74.02 and $81.82 Define the Nearby Reference Levels for the Current SessionHigh Dividend Factor - Vinanet
ANI Pharmaceuticals (NASDAQ:ANIP): What Could Shift Sentiment? - Kalkine Media
Rice Hall James & Associates LLC Takes Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript - AOL.com
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold - Sahm
Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth - Yahoo Finance
ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares - GuruFocus
ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan - Kalkine Media
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan - Stock Titan
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com - Investing.com Australia
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):